AnaptysBio Balance Sheet Health
Financial Health criteria checks 6/6
AnaptysBio has a total shareholder equity of $191.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $551.8M and $360.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$431.15m |
| Equity | US$191.09m |
| Total liabilities | US$360.70m |
| Total assets | US$551.79m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ANAB *'s short term assets ($437.2M) exceed its short term liabilities ($35.8M).
Long Term Liabilities: ANAB *'s short term assets ($437.2M) exceed its long term liabilities ($324.9M).
Debt to Equity History and Analysis
Debt Level: ANAB * is debt free.
Reducing Debt: ANAB * has no debt compared to 5 years ago when its debt to equity ratio was 4.5%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ANAB * has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ANAB * has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 13.1% each year.